1,2,3-triazoles (including Hydrogenated) Patents (Class 548/255)
-
Patent number: 11730811Abstract: The present invention discloses a method for treating a subject suffering from a Flavivirus infection. The method includes a step of administering to the subject a pharmaceutical composition including a pharmaceutically effective amount of an anti-CD44 antibody.Type: GrantFiled: March 17, 2021Date of Patent: August 22, 2023Assignee: KAOHSIUNG MEDICAL UNIVERSITYInventors: Yen-Hsu Chen, Chun-Yu Lin, Paraskevi Heldin
-
Patent number: 11639342Abstract: Compositions, methods, and kits for the labeling, detecting, isolating and/or analysis of biomolecules modified by attachment of chemical handles are disclosed.Type: GrantFiled: January 10, 2020Date of Patent: May 2, 2023Assignee: BIOCONJUGATE TECHNOLOGIES, LLCInventors: Andrei Polukhtin, Peter J. An, Alexandra Kulyashova, Jakub M. Labedz, Valentin A. Rassadin, Nikita V. Savelyev, Kostiantyn Ziabrev
-
Patent number: 11608329Abstract: The present invention provides AHR agonists, compositions thereof, and methods of using the same.Type: GrantFiled: December 18, 2020Date of Patent: March 21, 2023Assignee: IKENA ONCOLOGY, INC.Inventors: Alfredo C. Castro, Karen J. McGovern, Michael Burke
-
Patent number: 11389456Abstract: Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject is also provided.Type: GrantFiled: February 22, 2019Date of Patent: July 19, 2022Assignee: OxaluRx, Inc.Inventors: Bradley T. Keller, John J. Talley
-
Patent number: 10961201Abstract: The present application relates to the use of heterocyclic compounds for controlling animal pests including arthropods, insects and nematodes, to novel heterocyclic compounds, to processes for their preparation and to intermediates for preparing the heterocyclic compounds.Type: GrantFiled: August 9, 2019Date of Patent: March 30, 2021Assignee: Bayer Cropscience AGInventors: Eike Kevin Heilmann, Joerg Greul, Axel Trautwein, Hans-Georg Schwarz, Isabelle Adelt, Roland Andree, Peter Luemmen, Maike Hink, Martin Adamczewski, Mark Drewes, Angela Becker, Arnd Voerste, Ulrich Goergens, Kerstin Ilg, Johannes-Rudolf Jansen, Daniela Portz
-
Patent number: 10246427Abstract: 1,2,3-triazolyl cyclohexanol derivatives have been disclosed and their use as ligands accelerating the copper(I)-catalyzed azide-alkyne cycloaddition and the zinc(II)-catalyzed azide-nitrile cycloaddition.Type: GrantFiled: June 7, 2016Date of Patent: April 2, 2019Assignee: UNIWERSYTET JAGIELLONSKIInventors: Przemyslaw Szafranski, Patryk Kasza, Marek Cegla
-
Patent number: 10093633Abstract: The present invention provides novel functionalized mixtures 4- and 5-vinyl substituted regioisomers of 1,2,3-triazoles via 1,3-dipolar cycloaddition. Functionalized alkyne moieties with a terminal alcoholic functionality are reacted with functionalized organic moieties with a terminal leaving group and an azide to provide an alcoholic functionalized mixture of 4- and 5-substituted regioisomers of 1,2,3-triazole moieties. The mixture may be converted to a wide variety of useful functionalized mixtures of 4- and 5-vinyl substituted regioisomers of 1,2,3-triazole moieties, which in turn can be converted to a wide variety of useful polymers The novel alcoholic functionalized mixtures of 4- and 5-substituted regioisomers can be separated by chromatography to provide the purified 4- and 5-alcoholic functionalized substituted 1,2,3-triazole moieties. The novel compounds of the invention can be employed in a wide variety of compositions (Formulae (I), (II)); wherein R1, R2, R3, and R4, are defined herein.Type: GrantFiled: December 7, 2015Date of Patent: October 9, 2018Assignee: ISP Investments LLCInventors: Osama M. Musa, Brian Marr
-
Patent number: 10070645Abstract: The present invention relates to fungicidal N-cycloalkyl-N-{[2-(1-substitutedcycloalkyl)phenyl]methylene} carboxamide derivatives and their thiocarbonyl derivatives, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions.Type: GrantFiled: December 4, 2014Date of Patent: September 11, 2018Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFTInventors: Pierre Cristau, Philippe Desbordes, Julie Geist, Lionel Nicolas, Philippe Rinolfi, Jan-Peter Schmidt, Tomoki Tsuchiya, Jean-Pierre Vors, Ulrike Wachendorff-Neumann
-
Patent number: 9957294Abstract: A peptide is disclosed of the general structure: Z—W—Y, wherein Z and Y are independently a one to eight amino acid sequence wherein the amino acids are selected from glycine and alanine and W is a non-hydrolyzable pHis analogue. Such peptides can be used to produce sequence-independent anti-phosphohistidine antibodies. Also provided are antibodies that specifically bind to a peptide comprising a phosphohistidine (or a non-hydrolyzable pHis analogue) but fail to specifically bind to an identical peptide containing histidine instead of phosphohistidine.Type: GrantFiled: September 12, 2014Date of Patent: May 1, 2018Assignees: Salk Institute for Biological Studies, SanofiInventors: Magda Stankova, Fahad Al-Obeidi, Jacques Mauger, Robert A. Binnie, Tony Hunter, Jill Meisenhelder, Stephen Rush Fuhs
-
Patent number: 9650404Abstract: The invention relates to novel curcumin derivatives in which one or two of the phenolic groups have been modified.Type: GrantFiled: February 25, 2011Date of Patent: May 16, 2017Assignee: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORKInventors: Krishnaswami Raja, Alejandra Alonso, Probal Banerjee, Sukanta Dolai, Christopher Corbo, Saadyah Averick, Amit Mogha, Shawon Debnath
-
Patent number: 9321738Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, pulmonary fibrosis.Type: GrantFiled: June 17, 2013Date of Patent: April 26, 2016Assignee: HOFFMAN-LA ROCHE INC.Inventors: Stephen Deems Gabriel, Matthew Michael Hamilton, Matthew C. Lucas, Yimin Qian, Achyutharao Sidduri
-
Patent number: 9312499Abstract: Compounds having a structure of Formula I, where G1 has the formula having the structure are described. In the structure of Formula I: Z1 to Z24 are each independently selected from group consisting of carbon and nitrogen; p is an integer from 1 to 10; adjacent carbazole groups G11, G12, and G13 are each bonded together either by a 9N-2C bond or a 9N-3C bond; G1 can include at least one 9N-2C intercarbazole bond and at least one 9N-3C intercarbazole bond; L and G2 are each independently selected from the group consisting of alkyl, aryl, or heteroaryl, which may be further substituted; m and n are both integers; and m+n ranges from 1 to the maximum number of possible substituents on L. Formulations and devices, such as an OLEDs, that include the compound of Formula I are also described.Type: GrantFiled: January 5, 2015Date of Patent: April 12, 2016Assignee: UNIVERSAL DISPLAY CORPORATIONInventor: Lichang Zeng
-
Patent number: 9302997Abstract: A copper catalyzed click chemistry ligation process is employed to bind azides and terminal acetylenes to provide 1,4-disubstituted 1,2,3-triazole triazoles. The process comprises contacting a solution of an organic azide and a terminal alkyne with a source of catalytic Cu(I) ion to form a 1,4-disubstituted 1,2,3-triazole, wherein the source of Cu(I) ion comprises Cu(II) and a metal capable of reducing Cu(II) to Cu(I). In some embodiments, the metal capable of reducing Cu(II) to Cu(I) is selected from the group consisting of Al, Be, Co, Cr, Fe, Mg, Mn, Ni, and Zn.Type: GrantFiled: May 6, 2015Date of Patent: April 5, 2016Assignee: The Scripps Research InstituteInventors: K. Barry Sharpless, Valery Fokin, Vsevold A. Rostovtsev, Luke Green, Fahmi Himo
-
Patent number: 9073892Abstract: Compounds of Formula (I) are used for the treatment of inflammation and autoimmune disorders.Type: GrantFiled: December 16, 2011Date of Patent: July 7, 2015Assignee: Merck Serono S.A.Inventors: Catherine Jorand-Lebrun, Stefano Crosignani, Jerome Dorbais, Tania Grippi-Vallotton, Adeline Pretre
-
Publication number: 20150147273Abstract: A method for determining whether compound 0118 is a candidate treatment for a patient includes processing, via a processor, image data of tissue of interest of a patient including a cancer to determine whether a radiolabeled analog of compound 0118 is present in the tissue of interest represented in the image data and generating a signal indicating that compound 0118 is a candidate treatment for the patient in response to the determining that the radiolabeled analog of compound 0118 is present in a predetermined amount in the tissue of interest represented in the image data, wherein the presence of the radiolabeled analog of compound 0118 in the tissue of interest indicates presence of a sub-type of cancer having a galectin-1 molecular target, which is a sub-type of treatable by compound 0118.Type: ApplicationFiled: June 10, 2013Publication date: May 28, 2015Applicant: Koninklijke Philips N.V.Inventors: Tilman Lappchen, Holger Gruell, Marc Stefan Robillard, Johan Lub
-
Patent number: 9040716Abstract: A copper catalyzed click chemistry ligation process is employed to bind azides and terminal acetylenes to provide 1,4-disubstituted 1,2,3-triazole triazoles. The process comprises contacting an organic azide and a terminal alkyne with a source of reactive Cu(I) ion in human blood plasma to form by cycloaddition a 1,4-disubstituted 1,2,3-triazole. The source of reactive Cu(I) ion can be, for example, a Cu(I) salt, Cu(II) ion in the presence of a reducing agent, or copper metal.Type: GrantFiled: October 7, 2014Date of Patent: May 26, 2015Assignee: The Scripps Research InstituteInventors: K. Barry Sharpless, Valery Fokin, Vsevold A. Rostovtsev, Luke Green, Fahmi Himo
-
Patent number: 9039979Abstract: The present disclosure relates to an apparatus and process for forming medical devices from an injectable composition. The apparatus includes a supply assembly configured to maintain and selective dispense a first precursor and a second precursor, a mixing assembly configured to mix the first and second precursors, and at least one catalyzing element including a transition metal ion to aid in the polymerization of the first and second precursors. The process includes dispensing a volume of the first precursor and a volume of the second precursor into a mixing assembly and mixing the first and second precursors. The first and second precursors each possess a core and at least one functional group known to have click reactivity with each other. The mixed precursors are contacted with a transition metal catalyst to produce a flowable composition for use as a medical device.Type: GrantFiled: February 22, 2010Date of Patent: May 26, 2015Assignee: Sofradim ProductionInventors: Sébastien Ladet, Philippe Gravagna
-
Patent number: 9035068Abstract: The present invention relates to the phosphohistidine analogs of the present invention which of the formula (I) and the hapten containing the residue of same. It also relates to the hapten conjugated to a carrier molecule and the isolated antibodies raised against the immunogens, said antibodies recognizing polypeptide containing a phosphorylated histidine or the phosphotriazole residue but it does not recognize an amino acid or polypeptide that is not phosphorylated or a polypeptide which is phosphorylated on amino acids other than histidine but not on histidine.Type: GrantFiled: September 23, 2011Date of Patent: May 19, 2015Assignee: THE ROCKEFELLER UNIVERSITYInventors: Tom W. Muir, Jung-Min Kee
-
Publication number: 20150133511Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, pulmonary fibrosis . . . .Type: ApplicationFiled: June 17, 2013Publication date: May 14, 2015Inventors: Stephen Deems Gabriel, Matthew Michael Hamilton, Matthew C. Lucas, Yimin Qian, Achyutharao Sidduri
-
Publication number: 20150133658Abstract: In one aspect, the invention relates to compounds having the formula: where R1, R2a, R2b, R3-R6, a, b, Z, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.Type: ApplicationFiled: August 15, 2014Publication date: May 14, 2015Applicant: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Melissa Fleury, Roland Gendron, Adam D. Hughes, Cameron Smith
-
Publication number: 20150133512Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, pulmonary fibrosis.Type: ApplicationFiled: June 17, 2013Publication date: May 14, 2015Inventors: Stephen Deems Grabriel, Matthew Michael Hamilton, Yimin Qian, Achyutharao Sidduri
-
Publication number: 20150126708Abstract: The present invention provides a method of radio fluorination of biological targeting molecules (BTMs) with the radioisotope 18F. Also provided are novel conjugates useful in the 18F-radio fluorination method, and the use of such conjugates and automated synthesizer apparatus including cassettes for carrying out the method.Type: ApplicationFiled: December 20, 2012Publication date: May 7, 2015Applicants: IMPERIAL INNOVATIONS LIMITED, GE HEALTHCARE LIMITEDInventors: Sajinder Kaur Luthra, Robin Fortt, Ramala Osman Awais, Eric Ofori Aboagye, Graham Smith
-
Patent number: 9023864Abstract: Compound of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma.Type: GrantFiled: February 7, 2013Date of Patent: May 5, 2015Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.Inventors: Carl Berthelette, Michael Boyd, John Colucci, Karine Villeneuve, Joey L. Methot
-
Patent number: 9023318Abstract: Novel compounds and pharmaceutical compositions having MMP inhibitory activity are disclosed, which have been found to be particularly useful in the prevention, treatment and diagnostic imaging of diseases associated with an unpaired activity of MMP, amongst others MMP-2, MMP-8, MMP-9 and/or MMP-13 to name a few. The compounds of the present invention are useful for the prevention, the treatment and the in vivo diagnostic imaging of a range of disease states (inflammatory, malignant and degenerative diseases) where specific matrix metalloproteinases are known to be involved.Type: GrantFiled: March 25, 2013Date of Patent: May 5, 2015Assignee: Siemens Medical Solutions USA, Inc.Inventors: Gang Chen, Umesh B. Gangadharmath, Dhanalakshmi Kasi, Harmuth C. Kolb, Changhui Liu, Anjana Sinha, Anna Katrin Szardenings, Joseph C. Walsh, Eric Wang, Chul Yu, Wei Zhang, Klaus Kopka, Guenter Haufe, Michael Schaefers, Verena Hugenberg, Stefan Wagner, Sven Hermann, Hans-Joerg Breyholz, Andreas Faust
-
Publication number: 20150118179Abstract: Biocidally active cationic analogs of N-halamine having two biocidally active groups covalently bonded together in a single molecule and having general Formula (I). Compounds of Formula (I), and precursors thereof, can be in solution form immobilized onto a substrate via physical coating or covalent chemical bonding to functionalize surfaces or added into materials as additives so as to render them biocidal. The biocidal solutions and substrates comprising the compounds or precursors of the present invention can then be used to inactivate pathogenic microorganisms.Type: ApplicationFiled: May 16, 2013Publication date: April 30, 2015Applicant: UNIVERSITY OF MANITOBAInventor: Song Liu
-
Publication number: 20150111888Abstract: The present invention provides a small compound targeting at TACC3. The present invention further provides a drug, particularly, an anticancer agent, comprising the small compound targeting at TACC3. A compound represented by the general formula (I) or a pharmaceutically acceptable salt, solvate, or ester derivative thereof binds to TACC3 and inhibits cell growth. Thus, these compounds can be used as drugs, particularly, anticancer agents.Type: ApplicationFiled: April 30, 2013Publication date: April 23, 2015Inventors: Ryoji Yao, Hiroyuki Osada, Yasumitsu Kondoh
-
Publication number: 20150111875Abstract: The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.Type: ApplicationFiled: October 17, 2014Publication date: April 23, 2015Inventors: Wilhelm Amberg, Frauke Pohlki, Udo Lange, Ying Wang, Jason Brewer, Anil Vasudevan, Yanbin Lao, Charles Hutchins, Hongyu Zhao, Huan-Qiu Li
-
Publication number: 20150104387Abstract: Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described.Type: ApplicationFiled: April 2, 2014Publication date: April 16, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: MARTIN G. POMPER, RONNIE C. MEASE, YING CHEN, Sangeeta Ray
-
Publication number: 20150105378Abstract: The present invention provides compounds of Formula (I) or Formula (III): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.Type: ApplicationFiled: December 18, 2014Publication date: April 16, 2015Inventors: Lynn Abell, Leonard Adam, Cullen L. Cavallaro, Heather Finlay, Todd J. Friends, Jon J. Hangeland, Ji Jiang, R. Michael Lawrence, John Lloyd, Zulan Pi, George O. Tora, Jennifer X. Qiao, Carol Hui Hu, Tammy C. Wang
-
Patent number: 9006345Abstract: In one aspect, the present invention is directed to dendrimers comprised of macromolecules and trifunctional branches. In another aspect, the invention relates to methods for generating dendrimeric compositions comprising macromolecules and trifunctional branches. In certain embodiments, the radial density of the dendrimeric composition is controlled by selective incorporation of branches.Type: GrantFiled: March 26, 2012Date of Patent: April 14, 2015Assignee: The Trustees of Columbia University in the City of New YorkInventors: Jeffrey Lancaster, Jeffrey T. Koberstein, Nicholas J. Turro
-
Publication number: 20150099734Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, Y and W are as described herein, compositions including the compounds and methods of using the compounds.Type: ApplicationFiled: December 12, 2014Publication date: April 9, 2015Applicant: Hoffmann-La Roche Inc.Inventors: Daniel HUNZIKER, Patrizio MATTEI, Harald MAUSER, Marco PRUNOTTO, Christoph ULLMER
-
Publication number: 20150099781Abstract: Described herein are compounds, and pharmaceutically acceptable salts and prodrugs thereof, which are useful as inhibitors of IMPDH. In certain embodiments, a compound of the invention selectively inhibits a parasitic IMPDH versus a host IMPDH. Further, the invention provides pharmaceutical compositions comprising one or more compounds of the invention. The invention also relates to methods of treating various parasitic and bacterial infections in mammals. Moreover, the compounds may be used alone or in combination with other therapeutic or prophylactic agents, such as anti-virals, anti-inflammatory agents, antimicrobials and immunosuppressants.Type: ApplicationFiled: December 16, 2014Publication date: April 9, 2015Inventors: Lizbeth K. Hedstrom, Gregory D. Cuny, Deviprasad R. Gollapalli, Sivapriya Kirubakaran, Sushil K. Maurya, Boris Striepen, Suresh K. Gorla, Corey R. Johnson, Mandapati Kavitha, Jihan Khan
-
Publication number: 20150099696Abstract: The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The present invention is directed to compounds suitable for the treatment of Disease conditions such as hyperlipidemia.Type: ApplicationFiled: June 26, 2012Publication date: April 9, 2015Applicant: Cadila Healthcare LimitedInventors: Harikishore Pingali, Pankaj Makadia, Vrajesh Pandya, Sairam V.V.M. Kalapatapu
-
Publication number: 20150094294Abstract: The present disclosure provides compounds, specifically pyrimidin-4,6-dicarboxylic acid amide derivatives, or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing said compounds. Also provided are methods for treating a mammal having malaria, or killing or inhibiting the growth of a Plasmodium species, comprising administering to said mammal or contacting said Plasmodium species with, an effective amount of a pyrimidin-4,6-dicarboxylic acid amide derivative.Type: ApplicationFiled: February 28, 2013Publication date: April 2, 2015Inventors: Richard W. Scott, Robert W. Kavash, Wenxi Pan, Katie Freeman, Michael J. Costanzo, Doron Greenbaum, Yongjiang Xu, Trevor Young
-
Publication number: 20150094337Abstract: The present invention provides a heterocyclic group contained amino-methanol derivative, and salt, a preparation method and use thereof, and belongs to the medical field. The heterocyclic group contained amino-methanol derivative and the salt thereof of the present invention are used for preparing medicines for immune suppression and for the treatment of organ transplant rejection, or medicines for treating immune mediated inflammatory diseases, such as multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis.Type: ApplicationFiled: December 8, 2014Publication date: April 2, 2015Inventors: Xingmin Zhang, Ensi Wang, Jing Guo, Shengxiu Niu, Zhuolin Dai, Nan Zheng, Liping Ji, Zhenfang Wang, Tie Liang
-
Patent number: 8993698Abstract: The present invention provides novel 4- and 5-substituted 1,2,3-triazole moieties, with at least one remote polymerizable moiety. The novel mixtures of 4- and 5-substituted regioisomers of 1,2,3-triazole moieties can be separated by chromatography to provide the purified 4- and 5-substituted 1,2,3-triazole moieties. The novel mixtures of 4- and 5-substituted regioisomers of 1,2,3-triazole moieties, and the purified 4- and 5-substituted 1,2,3-triazole moieties, with at least one remote polymerizable moiety, can be converted to a wide variety of useful polymers. The novel compounds of the invention can be employed in a wide variety of compositions. E, Q, Z, X, a, and R1-R4, in the structures below, are defined herein.Type: GrantFiled: July 7, 2010Date of Patent: March 31, 2015Assignee: ISP Investments Inc.Inventor: Osama M. Musa
-
Publication number: 20150087827Abstract: The present invention relates to a process for preparing 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-ol (I—enol form) or 2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1,2-dihydro-3H-pyrazol-3-one (I—keto form) and sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate (II) from 1,2,3-triazole (III), methyl bromoacetate (IV-Me-Br) or ethyl bromoacetate (IV-Et-Br), 4,6-dichloropyrimidine (VIII), morpholine (IX) and hydrazine (XII).Type: ApplicationFiled: May 6, 2013Publication date: March 26, 2015Applicant: BAYER PHARMA AKTIENGESELLSCAFTInventors: Hans-Christian Militzer, Johannes Eggert
-
Patent number: 8981111Abstract: The present invention relates to hydroximoyl-heterocycle derivatives, their process of preparation, intermediate compounds for their preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.Type: GrantFiled: April 21, 2009Date of Patent: March 17, 2015Assignee: Bayer Cropscience AGInventors: Christian Beier, Jürgen Benting, David Bernier, Isabelle Christian, Pierre-Yves Coqueron, Philippe Desbordes, Christophe Dubost, Pierre Genix, Marie-Claire Grosjean-Cournoyer, Daniela Portz, Rachel Rama, Philippe Rinolfi, Arnd Voerste, Ulrike Wachendorff-Neumann
-
Patent number: 8980886Abstract: The present invention relates to novel anthranilic acid derivatives of the general formula (I) in which R1, R2, R3, R4, R5, Qx, A, Qy and n have the meanings given in the description, to their use as insecticides and acaricides for controlling animal pests, also in combination with other agents for activity boosting, and to a plurality of processes for their preparation.Type: GrantFiled: June 14, 2011Date of Patent: March 17, 2015Assignee: Bayer Cropscience AGInventors: Rüdiger Fischer, Christoph Grondal, Markus Heil, Heinz-Juergen Wroblowsky, Ernst Rudolf Gesing, Arnd Voerste, Ulrich Görgens
-
Publication number: 20150073026Abstract: Triazole derivatives useful as anti-tubercular compounds; process for preparation of the triazoles and a method for inhibiting growth of Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Ra using the triazoles.Type: ApplicationFiled: September 23, 2014Publication date: March 12, 2015Inventors: Dhiman SARKAR, Sunita Ranjan DESHPANDE, Shailaja Pramod MAYBHATE, Anjali Prabhakar LIKHITE, Sampa SARKAR, Arshad KHAN, Preeti Madhukar CHAUDHARY, Sayalee Ramchandra CHAVAN
-
Publication number: 20150065711Abstract: Disclosed are linear discrete PEG constructs, which can be created and produced in a precise and reproducible way. Key to being able to do these things, where x in the discrete PEGx can vary from about 2 to about 64, is that the processes used to make each linear portion is controlled to give essentially one oligomer/one compound. Having a variable length linear discrete PEG construct that is (a) primarily an linear discrete PEG construct with diagnostic or therapeutic groups attached along a chain of attachment cores, which is attached to a preferential locator; (b) is an m-discrete PEG as the terminal construct on the linear portion, and “hidden”; (c or linear discrete PEG with a terminus group that can be either negatively or positively charged, or neutral; and any of the discrete PEG portions can be designed to be cleaved after entering the cell.Type: ApplicationFiled: August 15, 2014Publication date: March 5, 2015Applicant: EquIP, LLCInventor: Paul D. Davis
-
Publication number: 20150065521Abstract: Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted triazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.Type: ApplicationFiled: April 18, 2013Publication date: March 5, 2015Applicant: Roche Palo Alto LLCInventor: Roche Palo Alto LLC
-
Patent number: 8962580Abstract: The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.Type: GrantFiled: September 23, 2009Date of Patent: February 24, 2015Assignee: Alnylam Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Takeshi Yamada, David Butler, Narayanannair K. Jayaprakash, Muthusamy Jayaraman, Shigeo Matsuda, Rajendra K. Pandey, Chang Geng Peng
-
Publication number: 20150045559Abstract: The present invention relates to novel compounds derived from oxoazetidine corresponding to general formula (I) to the compositions containing same, to the process for preparation thereof and to the use thereof in pharmaceutical or cosmetic compositions.Type: ApplicationFiled: September 26, 2014Publication date: February 12, 2015Inventors: Claire BOUIX-PETER, Itaru SUZUKI, Nicolas RODEVILLE, Pascale MAUVAIS, Jean-Claude PASCAL
-
Publication number: 20150045393Abstract: The invention provides for novel cysteine protease inhibitors and compositions comprising novel cysteine protease derivatives. The invention further provides for methods for treatment of neurodegenerative diseases comprising administration novel cysteine protease inhibitors or compositions comprising novel cysteine protease inhibitors. In some embodiments, the cysteine protease inhibitors are calpain inhibitors.Type: ApplicationFiled: February 1, 2013Publication date: February 12, 2015Inventors: Greg R. Thatcher, Isaac Thomas Schiefer, Ottavio Arancio, Mauro Fa
-
Publication number: 20150044233Abstract: Methods for determining the presence of cancer stem cells by detecting GD2 expression. Also provided are methods for reducing proliferation of cancer stem cells by contacting the cells with a GD2 targeting agent, such as an anti-GD2 antibody or a GD3 synthase inhibitor. GD3 synthase inhibitor compounds are also provided.Type: ApplicationFiled: February 27, 2013Publication date: February 12, 2015Inventors: Venkata Battula, Michael Andreeff, Sendurai A. Mani, Tapasree Roy Sarkar
-
Patent number: 8952042Abstract: The present invention relates to compounds of formula (1): where R, A, Q and Z are defined herein, or an enantiomer, diastereomer, tautomer, solvate, prodrug or pharmaceutical acceptable salt thereof. These compounds bind to the NR1H4 receptor (FXR) and act as agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.Type: GrantFiled: August 19, 2010Date of Patent: February 10, 2015Assignee: Phenex Pharmaceuticals AGInventors: Claus Kremoser, Ulrich Abel, Christoph Steeneck, Olaf Kinzel
-
Patent number: 8946426Abstract: The present invention is concerned with substituted bicyclic heterocyclic compounds of Formula (I) wherein Het1, Het2, A1, A2, A3 and A4 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: February 2, 2010Date of Patent: February 3, 2015Assignees: Janssen Pharmaceuticals, Inc., Cellzome LimitedInventors: Henricus Jacobus Maria Gijsen, Adriana Ingrid Velter, Gregor James MacDonald, François Paul Bischoff, Tongfei Wu, Sven Franciscus Anna Van Brandt, Michel Surkyn, Mirko Zaja, Serge Maria Aloysius Pieters, Didier Jean-Claude Berthelot, Michel Anna Jozef De Cleyn, Daniel Oehlrich
-
Patent number: 8946391Abstract: The present invention provides for a practical, universal and efficient method to ligate two large macromolecules (e.g., proteins) using the alkyne-azide 1,3-dipolar cycloaddition reaction to produce a conjugated macromolecule, such as a multivalent scFv. The present invention also provides for conjugate macromolecules comprising a plurality of macromolecule components cross-linked through at least one linking group comprising at least one 1,2,3-triazole moiety, wherein at least 50 percent of the macromolecule components in the conjugate macromolecule has only one site available for cross-linking.Type: GrantFiled: March 26, 2007Date of Patent: February 3, 2015Assignee: The Regents of the University of CaliforniaInventors: Jacquelyn Gervay-Hague, Wenjun Du, Sally Denardo, Arutselvan Natarajan
-
Publication number: 20150031738Abstract: The present invention provides compounds, or pharmaceutically acceptable salts thereof, for inhibiting the growth of a microbe; treating a mammal having a microbial infection, mucositis, an ophthalmic infection, an otic infection, a cancer, or a Mycobacterium infection; inhibiting the growth of a Mycobacterium species; modulating an immune response in a mammal; or antagonizing unfractionated heparin, low molecular weight heparin, or a heparin/low molecular weight heparin derivative.Type: ApplicationFiled: December 10, 2012Publication date: January 29, 2015Applicant: University of MassachusettsInventors: Yan Li, Hitest Thaker, Gregory N. Tew, Dahui Liu, Wenxi Pan